Regeneron and Teva to bar OA patients from fasinumab trials after US study halt

Regeneron and Teva to bar OA patients from fasinumab trials after US study halt

Regeneron and Teva to bar OA patients from fasinumab trials after US study halt
Regeneron and partner Teva announced that osteoarthritis patients would be excluded from future fasinumab research last night after the US Food and Drug Administration imposed a clinical hold on the study, which was assessing the drug as a chronic lower back pain treatment.“The US FDA has placed the Phase 2b study in chronic low back pain on clinical hold and requested an amendment of the study protocol after observing a case of adjudicated arthropathy in a patient receiving high dose fasinumab who had advanced osteoarthritis at study entry.”The firms added that although preliminary analysis indicates fasinumab’s safety profile is consistent with earlier studies they “plan to design a pivotal Phase 3 study in chronic low back pain that excludes patients with advanced osteoarthritis.”A Regeneron spokeswoman confirmed that the firm is continuing to evaluate the results to determine the cause of the adjudicated arthropathy.Commercialization dealThe clinical hold comes a month after Regeneron and Teva teamed up to develop and commercialize fasinumab in a deal that will see the Israeli drug firm pay $250m upfront and …

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>